Thus, the spike-specific IgA and IgG antibodies were measurable in the BNT162b2 mRNA vaccinated and the COVID-19 convalescent HIV-1-infected patients, but both the serum IgA levels and the neutralizing capacity at a 1:101 dilution were significantly lower compared to the HIV-1-uninfected subjects in a multivariate linear regression analysis. This evidence concerns the gene CD79A and COVID-19.